The peptides are derived from the plasma protein chemerin and work by reducing the production of inflammatory signaling proteins called cytokines which play a central role in the body's response to infection and injury. They are also implicated in the excessive immune responses underlying inflammatory diseases. The peptides inhibit activated antigen presenting cells by reducing the production of inflammatory cytokines including IL-12/23, TNFalpha, RANTES, IL-6 and IL-1beta.
Isis has granted Rogne an exclusive, world-wide licence to the associated patents.
The initial work in Professor Greaves' lab investigating inflammation was funded by the British Heart Foundation in the context of possible novel anti-inflammatory treatments for cardiovascular disease. Professor Jeremy Pearson, Associate Medical Director at the Foundation, said: "We are delighted that the research we funded has now led to a potential new anti-inflammatory treatment for psoriasis."
Isis Innovation Ltd
Rogne Bioscience, Inc.
About Isis Innovation
Isis Innovation is the research and technology commercialisation company of the University of Oxford. We provide access to technology from Oxford researchers through intellectual property licensing, spin-out company formation and material sales, and to academi
|SOURCE Rogne Bioscience, Inc.; Isis Innovation Ltd|
Copyright©2014 PR Newswire.
All rights reserved